AI’s Role in Reducing Healthcare Waste and Cost

By Michael Awood

October 19, 2023

Healthcare expenditure continues to rise, despite advances in medical training and technology. We’ve touched on this before, using an example from the US, where they have experienced these escalating costs. This was largely healthcare expenditure waste. Unfortunately, underperforming public services and poor health outcomes have been coupled with this. This, however, created the shift towards more efficient, cost-effective solutions. One such solution is the use of Artificial Intelligence (AI) in healthcare, and its role in reducing healthcare waste and cost.

AI has the potential to dramatically reduce inefficiencies in the healthcare system, leading to a more streamlined and cost-effective health ecosystem. This integration into healthcare is able to transform the approach to patient safety, hospital administration, drug development, and treatment decisions. AI is paving the way for rapid care management, enabling healthcare professionals to access real-time patient information at the touch of a button. This ability to quickly access and analyse patient data can significantly reduce casualties in emergency situations. The main outcome created is that of value

 

 The Economic Implications of AI in Healthcare

A start-up, backed by the University of Toronto, recently created a supercomputer algorithm to evaluate millions of potential Ebola treatments. This breakthrough creates value through cost and time reduction, and more importantly, it saves lives by improving existing treatments. With consumers (patients) increasingly using wearables, AI utilises this data for early detection of disease. This again reduces healthcare costs. In the referenced study it showed that AI significantly reduces healthcare costs compared to conventional methods.

The cost-saving due to AI used in treatment which has been found to be more effective than in diagnosis. AI not only enhances diagnostic accuracy but also minimizes inaccurate examinations, comforting patients.  In terms of time, AI-assisted tools require less time for diagnosis, resulting in cost savings. For instance, in the initial year, the time savings amount to 3.33 hours per day, and by the tenth year, the time saving reaches 15.17 hours per day. 

 

The Future of AI in Healthcare

AI must meet established quality requirements and importantly regulatory bodies must certify it. This will assist in the utilisation within healthcare, leading to full integration into existing systems. It would be important to conduct an economic analysis to compare the costs of AI-based diagnosis and treatment approaches with conventional approaches. These results show that it can significantly reduce healthcare costs compared to conventional methods.

AI possesses the potential to optimise the healthcare industry by reducing costs, improving efficiency, and enhancing patient care. However, to fully realise this potential, it is crucial to integrate AI into healthcare in a way that is economically viable and meets established quality standards.

 

Cover and in-text images taken from the article in the reference URL below

Reference url

Recent Posts

MASLD CKD socioeconomic link
    

Exploring the MASLD CKD Socioeconomic Link

🌍 Are socioeconomic factors influencing your health more than you realise?

Our latest article looks into the intriguing link between Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Chronic Kidney Disease (CKD), revealing significant geographical and socioeconomic correlations. Discover how understanding these relationships can inform public health strategies and improve health equity worldwide.

Dive into the findings and implications for health outcomes!

#SyenzaNews #HealthEconomics #globalhealth #HealthcareInnovation

toripalimab nasopharyngeal carcinoma
        

Toripalimab Evidence Journey in Cancer Care

🚀 How did toripalimab become the first immunotherapy approved in the U.S. for nasopharyngeal carcinoma?

The toripalimab evidence journey began with clinical trials in Asia. The JUPITER-02 trial showed toripalimab plus chemotherapy extended median progression-free survival (PFS) to 21.4 months versus 8.2 months with chemotherapy alone

#SyenzaNews #oncology #HealthcareInnovation

blood cancer treatments
        

NICE Breakthrough: Record Positive Recommendations for Blood Cancer Treatments in 2024

🚀 The National Institute for Health and Care Excellence (NICE) has made great strides in 2024, reporting a record number of positive recommendations for blood cancer therapies. This pivotal moment not only accelerates patient access to advanced treatments but also highlights the importance of precision medicine in oncology care.

Curious to learn how these advancements are reshaping the healthcare landscape and improving patient outcomes? Explore the full article for insights!

#SyenzaNews #oncology #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.